С. И. Шрам

463 citations

57 papers · 373 indexed · h-index 13

Co-authors: N. F. Myasoedov А. Н. Хохлов М. И. Шадрина Д. Н. Силачев Yu. A. Zolotarev Vladislava Gusar Angelika V. Timofeeva Pinelis Vg
Topics: PARP inhibition in cancer therapy (10 papers)Biochemical effects in animals (7 papers)DNA Repair Mechanisms (6 papers)
Cited by: Aging Behavioral Neuroscience Biochemistry
Journals: SHILAP Revista de lepidopterologíaFEBS Letters International Journal of Molecular Sciences
Partner nations: Russia Tajikistan United Kingdom

In The Last Decade

С. И. Шрам

54 papers receiving 361 citations

Peers

Countries citing papers authored by С. И. Шрам

Since Specialization

Citations

This map shows the geographic impact of С. И. Шрам's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by С. И. Шрам with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites С. И. Шрам more than expected).

Fields of papers citing papers by С. И. Шрам

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by С. И. Шрам. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by С. И. Шрам. The network helps show where С. И. Шрам may publish in the future.

Co-authorship network of co-authors of С. И. Шрам

This figure shows the co-authorship network connecting the top 25 collaborators of С. И. Шрам. A scholar is included among the top collaborators of С. И. Шрам based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with С. И. Шрам. С. И. Шрам is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A New Approach for Studying Poly(ADP-Ribose) Polymerase Inhibitors Using Permeabilized Adherent Cells 2024 ·Biochemistry (Moscow) ·С. И. Шрам,(unknown),Tatyana V. Abramova,(unknown),(unknown),А. В. Куликов,Vytas K. Švedas,Vladimir N. Silnikov,N. F. Myasoedov,D. K. Nilov	1
2	NEUROPROTECTIVE EFFECT OF HLDF-6-H PEPTIDE IN PARKINSON'S DISEASE. 2024 ·Yu. A. Zolotarev,О. В. Долотов,Dmitrii D. Markov,С. И. Шрам,A. K. Dadayan,Н. В. Кост,O. Yu. Sokolov,(unknown),(unknown),(unknown)	0
3	Natural guanine derivatives exert PARP-inhibitory and cytoprotective effects in a model of cardiomyocyte damage under oxidative stress 2023 ·С. И. Шрам,(unknown),(unknown),(unknown),(unknown),(unknown),Vladimir N. Silnikov,Vytas K. Švedas,D. K. Nilov	1
4	Influence of Dinitrosyl Iron Complexes on the Activity of Enzymes, Indicators of Cardiovascular Diseases 2022 ·Biointerface Research in Applied Chemistry ·Natalia Akentieva,Н. А. Санина,(unknown),(unknown),Anna Andreeva,С. И. Шрам,С. М. Алдошин,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	1
5	Intracytoplasmic Trafficking of Nanoparticles based on Hyaluronic Acid and Chitosan for Targeted Delivery of Anticancer Drugs 2022 ·Biointerface Research in Applied Chemistry ·Natalia Akentieva,(unknown),Н. А. Санина,(unknown),(unknown),Vladimir E. Tikhonov,С. И. Шрам,С. М. Алдошин,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	4
6	Inhibitory Effects of 7-Methylguanine and Its Metabolite 8-Hydroxy-7-Methylguanine on Human Poly(ADP-Ribose) Polymerase 1 2022 ·Biochemistry (Moscow) ·(unknown),С. И. Шрам,Mikhail M. Kutuzov,Tatyana V. Abramova,(unknown),Ekaterina A. Maltseva,Vladimir Poroikov,Olga I. Lavrik,Vytas K. Švedas,D. K. Nilov	3
7	HLDF-6 peptides exhibit neuroprotective effects in the experimental model of preclinical Parkinson's disease 2022 ·Neuropeptides ·Yu. A. Zolotarev,С. И. Шрам,(unknown),О. В. Долотов,Dmitrii D. Markov,I. Yu. Nagaev,В. С. Кудрин,В. Б. Наркевич,O. Yu. Sokolov,Н. В. Кост	2
8	Pharmacokinetics and Molecular Modeling Indicate nAChRα4-Derived Peptide HAEE Goes through the Blood–Brain Barrier 2021 ·Biomolecules ·Yu. A. Zolotarev,Vladimir A. Mitkevich,С. И. Шрам,Alexei A. Adzhubei,(unknown),(unknown),A. K. Dadayan,(unknown),Alexander А. Makarov,Sergey A. Kozin	9
9	Biological Diversity and Remodeling of Cardiolipin in Oxidative Stress and Age-Related Pathologies 2019 ·Biochemistry (Moscow) ·(unknown),(unknown),В. В. Ашапкин,(unknown),Vassily Lyubetsky,(unknown),С. И. Шрам,А. В. Марков,M. Yu. Vyssokikh	13
10	Cytoprotective Effects of Dinitrosyl Iron Complexes on Viability of Human Fibroblasts and Cardiomyocytes 2019 ·Frontiers in Pharmacology ·Natalia Akentieva,Н. А. Санина,(unknown),(unknown),(unknown),С. И. Шрам,Nikolai Zhelev,С. М. Алдошин	13
11	Protein poly(ADP-ribosyl)ation system: Changes in development and aging as well as due to restriction of cell proliferation 2017 ·Biochemistry (Moscow) ·(unknown),С. И. Шрам,(unknown),А. Н. Хохлов	8
12	EFFECT OF PEPTIDE SEMAX ON SYNAPTIC ACTIVITY AND SHORT-TERM PLASTICITY OF GLUTAMATERGIC SYNAPSES OF CO-CULTURED DORSAL ROOT GANGLION AND DORSAL HORN NEURONS 2015 ·PubMed ·(unknown),N. S. Veselovsky,N. F. Myasoedov,С. И. Шрам,S. А. Fedulova	4
13	Doxorubicin causes transient activation of protein poly(ADP-ribosyl)ation in H9c2 cardiomyocytes 2015 ·Doklady Biochemistry and Biophysics ·(unknown),С. И. Шрам,(unknown)	4
14	The protein poly(ADP-ribosyl)ation system: Its role in genome stability and lifespan determination 2013 ·Biochemistry (Moscow) ·(unknown),А. Н. Хохлов,С. И. Шрам	12
15	Twelve-week Streptozotocin-induced Diabetes In Rats Does Not Cause Significant Retinal Degeneration, But Upregulates Heat Shock Protein Response 2012 ·Investigative Ophthalmology & Visual Science ·(unknown),(unknown),Giedrius Kalesnykas,С. И. Шрам	1
16	Isolation and Characterization of High Affinity Aptamers Against DNA Polymerase Iota 2012 ·Nucleic Acid Therapeutics ·А. В. Лахин,(unknown),Аlena V. Makarova,Youri I. Pavlov,(unknown),С. И. Шрам,В. З. Тарантул,Л. В. Генинг	14
17	Transcriptomic response of rat hippocampus and spleen cells to single and chronic administration of the peptide selank 2010 ·Doklady Biochemistry and Biophysics ·(unknown),М. И. Шадрина,(unknown),С. И. Шрам,(unknown),Limborskaia Sa,N. F. Myasoedov	8
18	Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex 2006 ·Bulletin of Experimental Biology and Medicine ·(unknown),Д. Н. Силачев,(unknown),(unknown),(unknown),С. И. Шрам,N. F. Myasoedov	15
19	Effect of Semax Peptide on Survival of Cultured Rat Pheochromocytoma Cells during Oxidative Stress 2003 ·Bulletin of Experimental Biology and Medicine ·(unknown),С. И. Шрам,Yu. A. Zolotarev,N. F. Myasoedov	11
20	Enzyme Self-Inactivation Is a Main Limitation of the Preparation of Eicosanoids: Enzymatic Synthesis of Thromboxane and 12(S )-Hydroxytetraenoic Acid 1999 ·Applied Biochemistry and Biotechnology ·С. И. Шрам,(unknown),(unknown),S.D. Varfolomeyev	2

About С. И. Шрам

С. И. Шрам is a scholar working on Pharmaceutical Science, Biochemistry and Developmental Neuroscience, having authored 57 papers that have together received 373 indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (10 papers), Biochemical effects in animals (7 papers) and DNA Repair Mechanisms (6 papers). The work is most often cited by research in Aging (11 citations), Behavioral Neuroscience (15 citations) and Biochemistry (29 citations). С. И. Шрам has collaborated with scholars based in Russia, Tajikistan and United Kingdom. Frequent co-authors include N. F. Myasoedov, А. Н. Хохлов, М. И. Шадрина, Д. Н. Силачев, Yu. A. Zolotarev, Vladislava Gusar, Angelika V. Timofeeva, Pinelis Vg, P. A. Slominsky and А. A. Tykhomyrov. Their work appears in journals such as SHILAP Revista de lepidopterología, FEBS Letters and International Journal of Molecular Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact